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[571 ABSTRACT 
Novel fluorohydrocarbons include a fluoroalkyl unit 
terminating in a tertiary carbon atom which is directly 
linked to an aliphatic moiety of the compound. The 
compounds contain at least 9 carbon atoms and usually 
no more than 13 carbon atoms. The compounds are 
synthesized by addition of a fluoride atom to the tertiary 
carbon atom of a fluorocarbon material to form a carb- 
anion followed by alkylation of the carbanion. The 
fluorohydrocarbons will find use as blood substitutes or 
as electronic fluids. 
11 Claims, No Drawings 
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NOVEL FLUOROHYDROCARBONS 
ORIGIN OF THE INVENTION 
The invention described herein was made in the per- 
formance of work under a NASA contract and is sub- 
ject to the provisions of Section 305 of the National 
Aeronautics and Space Act of 1968, Public Law 83-568 
(72 Stat. 435; 42 USC 2457). 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
The present invention relates to novel fluorohydro- 
carbons, to their synthesis and use. 
2. Description of the Prior Art 
Fluorocarbon compounds due to their inertness have 
found use as electronic coolant or leak testing fluids. 
Other compounds having good solubility for oxygen 
have been investigated as artificial blood substitutes. 
However, the present fluorocarbons are unduly expen- 
sive due to the high content of fluorine and the method 
of synthesis. Furthermore, the principal industrial pro- 
cesses employed in their synthesis, namely electrochem- 
ical fluorination or cobalt trifluoride fluorination do not 
result in pure substances but mixtures of compounds 
containing impurities and incompletely fluorinated 
compounds. Pure substances of known structure are 
desired for clinical applications. 
Another problem with fluorocarbon materials is that 
the excellent inertness of these materials prevents their 
active excretion through metabolic processes so that 
there appears to be no mechanism for their elimination 
from the body, other than by diffusion to and evapora- 
tion through the skin or lungs. Even though these 
chemicals are inert there is a risk in allowing them to 
remain indefinitely in body tissues. 
It has recently been proposed that by choosing fluo- 
rochemicals of sufficiently high vapor pressure their 
eventual elimination via the lungs and skin can be as- 
sured. While such an approach has merit it appears 
likely that in large animals such as dogs and probably 
man enough of these chemicals will be absorbed in 
depot fat or in brain or spinal cord lipids from which 
their subsequent clearance will be very slow indeed. 
Since many “inert” fluorochemicals have anesthetic 
properties, subtle behavioral changes in higher mam- 
mals might result from such incorporation. 
SUMMARY OF THE INVENTION 
Novel fluorocarbon hybrid materials with hydrocar- 
bon fragments are provided in accordance with the 
invention. The hybrid compounds are made by a syn- 
thetic route assuring production of pure substances in 
high yield and at low cost from readily available materi- 
als. The hybrid compounds have good oxygen and 
carbon dioxide solubility, exhibit high vapor pressure 
and will cost less than available electronic fluids or 
proposed blood substitute compounds. 
The problem of accumulating fluorocarbon com- 
pounds within body tissue is obviated by attachment of 
a metabolically reactive hydrocarbon handle to the 
larger fluorocarbon unit so that the physical properties 
responsible for good oxygen solubility are retained, yet 
a reactive site is available in the molecule on which the 
body’s general-purpose detoxifying enzymes can oper- 
ate and attach solubilizing conjugating groups such as 
taurine, glycine, glutamate, sulfate or glucuronate, per- 
mitting gradual renal or hepatic excretion via known 
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pathways. It is not required that all or even most of the 
hybrid compounds be excreted by this active mode 
since the vapor pressure of the hybrids is controlled so 
that a large fraction of the elimination takes place via 
the passive evaporative route. The hybrid compounds 
of the invention are unique in providing the additional 
metabolic mechanism of excretion to permit more rapid 
or more complete final clearance of the foreign com- 
pound from the body. 
The metabolism of the foreign chemical can be ad- 
justed to a half-life of days or weeks so that the blood 
substitute will not be eliminated before it has served its 
purpose and so that the detoxifying enzymes will not be 
overloaded. A further advantage of the hybrid com- 
pounds is that the hydrocarbon portion could also serve 
as the location of a *3C, 14C, 2H or 3H label, simplifying 
synthesis of labelled blood substitutes for research or as 
the site for attachment of a hydrophilic unit to create a 
highly fluorochemical-compatible surfactant for form- 
ing very stable emulsions. 
The hydrocarbon moiety can be selected based on 
metabolic considerations. Alkanes provide a reactive 
site for slow enzymatic attack via a, /3, or w-hydroxyla- 
tion in the liver microsomes. Thus, the alkyl side chains 
of barbituates and BHT, the antioxidant, are extensively 
hydroxylated and the compounds subsequently ex- 
creted as the more water soluble oxidized compounds 
or as the sulfate or glucuronide conjugates even though 
the R-CH3 groups attacked are unactivated in any 
chemical sense. Saturated n-alkanes are known to be 
oxidized readily to fatty acids in the rat. Both primary 
and secondary C-H bonds can be attacked. Oxidized 
higher hydrocarbons at a higher oxidation state, e.g., 
ethers such as -CH20CH3, alcohols such as -CH- 
zOH, or esters such as -CHzCOzR and the like, might 
speed up the conjugation and excretion of the fluoro- 
chemical in case the alkane group is oxidized too 
slowly; on the other hand, an iso- or neo-alkyl side 
chain would probably be attacked more slowly. 
In order to minimize toxicity or possible toxicity it is 
necessary that the connection between the fluoroalkyl 
moiety and the hydrocarbon portion of the molecule be 
designed to minimize the possibility of enzymatic or 
non-enzymatic degradation reactions proceeding past 
the linkage and breaking down the fluoroalkyl unit, 
liberating fluoride ion or toxic fluoroolefms. Such deg- 
radation is prevented in the hybrid compounds of the 
invention by terminating the fluoroalkyl unit in a ter- 
tiary carbon connected to a methylene atom which links 
the unit to the hydrocarbon portion of the hybrid mole- 
cule. Thus, as long as the connecting bond remains 
intact, there will be no labile fluorine atoms situated a 
to a hydrogen atom. The chemical lability of such C-F 
bonds is well known and probably accounts for the 
toxicity of partly fluorinated straight-chained com- 
pounds. Elimination of HF from such compounds 
would yield fluoroolefms, members of a class of com- 
pounds which is generally quite toxic and which in- 
60 cludes the most toxic fluorochemicals outside of the 
nerve gases. 
The novel hybrid compounds of the invention will 
find use as electronic test fluids, electronic cooling flu- 
ids and other fields where oxygen absorption is required 
65 such as enriched air for coal gasification. The hybrid 
compounds will find biologic use as a liquidfliquid ex- 
tracorporeal oxygenator that carries oxygen from a gas 
source of bubbles to blood in a liquidfliquid interface 
4,173,654 
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oxygenator designed to minimize blood damage. The 
hybrids will also find use in liquid breathing. Fluoro- 
chemical blood substitutes have been utilized in organ 
perfusions to maintain the viability and function of or- 
perfusate. Artifical blood preparations could have many 
applications including use as an emergency OxYgen-car- 
rYi% Plasma expander in cases of bleeding in shock, 
exchange transfusion of newborns with erythroblastosis 
fetalis, patients in sickle-cell crisis, patients in various 10 
toxic states and patients suffering from drug overdoses 
and carbon monoxide poisoning; transfusion of patients 
whose religious convictions preclude the use of blood; 
major surgery requiring large amounts of blood; and 
priming of heart-lung and dialysis machines as well as 
such extracirculatory uses as lung lavage in cases of 
smoke inhalation and other pulmonary diseases, and where X is an electrophilic group such as iodide or 
topical application in skin ulcers, burns and the like. bromide. 
These and many other features and attendant advan- A variety of fluoroolefins are available from anionic 
tages of the invention will become apparent as the in- 2o oliogomerization of tetrafluorethylene (TFE); hexa- 
vention becomes better understood by reference to the fluoropropene (HFP), and octafluoro-2-methyl propene 
following detailed description. (perfluoroisobutene, PFIB). Representative perfluon- 
nated compounds are shown below: DESCRIPTION O F  THE PREFERRED 
7' 7' terl 
Rj-C=CFCnF2,+1 + F- +Rj-Ce=Rp 
I gans or brain tissue in a fluorocarbon oxygen-carrying 5 Ri' 
The tertiary fluorocarbon can in turn undergo alkyla- 
tion or reaction with an electrophilic reagent to form a 
hybrid compound as follows: 
R y  + XR + R F R  + X- 
or 
2 R)3 + XRX + R p R - - R F "  + 2X lert 
EMBODIMENTS 25 
The hybrid compounds of the invention have the 
following essential structure: 
1 
I1 
R Y Z  30 /LA. 111 
CnF2n+ I 
I 
I 
Cn+2n**+ 1 
where R F  = C n * F m C -  IV 
V 
VI 
6 35 and CnF2n + 1 Rf=Cn,Rn'+ I 
Rf'=Cn,*F2n"+ 1 
and n, n', n" are integers from 1 to 11 and Z is the meta- 40 
bolically active hydrocarbon moiety. The hybrid com- 
pound can have from 6 to 15 carbon atoms in the case of 
electronic fluids or other uses but for clinical blood 
substitutes the hybrid compound should contain from 9 
to 13 carbon atoms and the vapor pressure of the com- 45 
pound should be <50 mm Hg at body temperature, 37" 
C. to 39" C., and the oxygen solubility should be at least 
30 volume percent at 37.5" C. 
The Z group should contain at least 2 hydrogen 
atoms and is preferably without unsaturation. Represen- 50 organic Chemistry," Wiley, N.Y. 1973. 
tative hydrocarbon groups are: 
x- 
Compound I is a dimer of HFP, I1 is the co-dimer of 
HFP and PFIB, 111-V are trimers of HFP and VI is a 
pentamer of TFE. The mechanisms of these oliogomeri- 
zations are described in R. D. Chambers, "Fluorine in 
The fluoride ion is present in at least a stoichiometric 
amount usually as a Group I metal salt such as KF, CsF, 
AgF or CuF. The reaction is usually conducted in a 
polar solvent such as dimethylformamide. 
-CH~-(CHZ)~-H 
55 Examples of practice follow: -CH2-(CH2)m-O-R 
-CH2-(CH2)m-OH EXAMPLE 1 
-CH2-(CH2)m-C02R 
CF3 
I 
I 
CF3 
CF3 
60 I 
I 
CF3 
where m is an integer from 0 to 8 and R is an alkyl or Synthesis of CF3-C-CH2-CH2-CH2-C-CF3 
substituted alkyl group containing non-interfacing, non- 
toxic groups such as hydrophilic groups. Straight chain 
alkyls are preferred from metabolic considerations. 
ion, F-, to a perfluoroolefin to form an intermediate 
general reaction: 
The hybrids are synthesized by addition of a fluoride 65 (CF3)2C=CF2 + I-CH2-CH2-CH2-I 
DMF 
tertiary fluorocarbanion according to the following (CF3)3C-CH2-CH2-CH2-C(CF3)3 
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102 Grams (0.34 mol) of 1,3-diiodopropane, 41 grams 
(0.71 mol) of dry potassium fluoride and 200 ml. of dry 
dimethylformamide were placed in a 500 ml. round 
bottomed three necked flask equipped with a cold fin- 
ger, gas inlet tube, septum and magnetic stirring. 189 
Grams (0.94 mol) of perfluoroisobutene was distilled 
into the pot. After 6 hours of stirring with the cold finer 
charged, the pot contents were placed in a separatory 
funnel with water and the lower fluorocarbon layer 
removed. The crude mixture was separated on a 8 
inchx 10 foot 20% FFAP G.C. column at 150" C. with 
a He flow of 150 ml/min. The first of two peaks was 
1,3-bis(perfluoro-tert-butyl) propane which solidified at 
room temperature. Sublimation of the product yielded 
49 grams (0.102 mol) of material melting at 32"-33" C. 
This was 30% of the theoretical yield based upon start- 
ing 1,3-diiodopropane. 
EXAMPLE 2 
CF3 
I 
CF3 
I 
I I 
CF3 CF3 
Synthesis of CF~-C-CH~-CH~-CH~-CH~-C-CFJ 
(CF~)ZC=CFZ + I-CH2-CH2-CH2-CH2-I 
DMF 
(CF3),C-CH2-CH2-CH2-CH2-C(CFj)j 
74 Grams (0.24 mol) of 1,4diiodobutane, 40 grams (0.69 
mol) of dry potassium fluoride and 200 ml. of dry di- 
methylformamide were placed in a 500 ml. round bot- 
tomed three necked flask equipped with a cold finger, 
gas inlet tube, septum and magnetic stirring. 130 grams 
(0.65 mol) of perfluoroisobutene was distilled into the 
pot. After 6 hours of stirring with the cold finger 
charged, the pot contents were placed into a separatory 
funnel with water and the lower fluorocarbon layer 
removed. The crude mixture was cooled to 0" C. and 
the solid collected by filtration. The crude l,+bis(per- 
t-butyl) butane was recrystallized twice from 
methanol yielding 38.4 grams (0.080 mol) of solid sub- 
liming in an open capillary at 130" C. This was a 32% 
yield based upon starting 1,Cdiiodobutane. 
EXAMPLE 3 
CF3 
I 
CF3 
I 
I ,  I 
CF3 CF3 
Synthesis of CF~-C-CHZ-CH=CH-CH~-C-CF~ 
(CF&C=CF2 + BrCH2-CH=CH-CH2-Br 
DMF 
(CF3)3C-CH2-CH=CH-CH2-C(CF3)3 
49.6 Grams (0.232 mol) of 1,4-dibromo-2-butene, 3 1.2 
grams (0.537 mol) of dry potassium fluoride and 150 
grams of dry dimethylformamide were placed in a 500 
ml. round bottomed three necked flask equipped with a 
cold finger, gas inlet tube, septum, and magnetic stir- 
ring. 113 Grams (0.563 mol) of perfluoroisobutene was 
distilled into the pot. After 6 hours of stirring with the 
cold finger charged, the pot contents were placed in a 
separatory funnel with water and the lower fluorocar- 
bon layer removed. The crude mixture was then cooled 
to 0" C. and the 1,4-bis(perfluoro-t-butyl)-2-butene crys- 
6 
tallized out. The solid was separated by filtration and 
recrystallized from methanol. A 70% yield based upon 
1,4-dibromo-2-butene was obtained, melting at p0+75" 
C. A second recrystallization from methanol yields pure 
EXAMPLE 4 
Synthesis of 
5 material melting at 78.5"-79.5" C. 
,o CF3-CF2-CF2-C(CF3)2-CH2-CH=CH2 
/F 
(CFj)zC=C 
CF~CFJ t 
BrCH2-CH=CHz > 
\ 
15 
KF 
DMS0,R.T. 
4 days 
CF3 
I 
I 
CF3 
20 CF3CF2CF2-C-CH2-CH=CH2 
30 Grams (0.10 mol) of perfluoro-2-methyl-2-pentene, 
25 13 grams (0.1 1 mol) of allyl bromide and 9 grams (0.16 
mol) of dry potassium fluoride placed in a 100 ml. round 
bottomed single necked flask fitted with a dry tube and 
stirred magnetically for 4 days. The pot contents are 
then washed with water in a separatory funnel with 
30 water and the lower fluorocarbon layer separated. The 
crude product is dissolved in anhydrous ether and dried 
with MgS04. The product is filtered and fractionally 
distilled. 18 Grams (0.05 mol) of product was collected 
boiling at 119" C. This was 50% of the theoretical yield 
EXAMPLE 5 
Synthesis of (CF3)3C--CF=CFCF3 
35 based on starting fluoroolefin. 
F ~ C - C F ~  
45 
CF3-CFSCF2 -> 
DMF,R.T. 
(CFJ)~C-CF=CF-CFJ 
Octafluorocyclobutane is pyrolysed in a furnace with a 
nickel tube measuring 12 inches in length and 1 foot in 
50 diameter at 750" C. with a gas flow of 2+3 ml/min. The 
effluent gases, which are principally perfluoroisobutene 
and hexafluoropropene, are condensed with a dry irc- 
acetone cold finger into dry dimethylformamide con- 
taining dry potassium fluoride. A lower fluoroolefin 
55 layer forms from which the product can be distilled, 
The above synthesis provides a novel perfluoroolefin 
suitable for forming hybrids. The compound is readily 
synthesized from available materials. 
Oxygen solubilities were measured at 25' C. and 760 
mm 0 2  pressure for representative hybrid, fluoroolefin 
and prior art compounds by means of a gas chromato- 
graph having a thermal conductivity detector and cal- 
65 culated from molar volume and AH(vap) by the method 
of Fedors (Polymer, Engr. Sci. 14 147 (1974). Good 
agreement was obtained as shown in the following ta- 
ble: 
bp=71"-72" C. 
7 
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Calculated 0 2  Measured 
Fluorochemical Material Solubility Solubility Literature Values 
(FC) cc 02 /100  cc FC cc 02/100 cc FC or other data 
( C F ~ ) ~ C - ( C H Z W H ~  43.2 
0 34.6 
II V = 205.5 
(CF3)3C-CH2COC2H5 6 = 7.39 
BP = 53" C./36mm 
V = 180.31 
S = 6.0 
BP = 76" C./735mm 
39.5 D = 1.820 
V = 219.8 
S = 6.4 
BP = 110' C./735mm 
(CF3)3C-CH2CH=CH2 44.1 48 D = 1.442 
36.8 3M solubility data 
38.9 cc Od100ccFC 
(n-C4F9)3N(FC43) 38.9 
41.2 D = 1.393 g/cc 
V = 198.3 c c h o l e  
S =5.98 Hb 
BP = 101.5" C./750mm 
34.4 D = 1.4895 
8 
Fluorochemicals are not soluble in water and sponta- 
neously forming emulsions are the exception. Mechani- 
cal or ultrasonic mixing in the presence of surfactants 
reduces the particles or droplets of fluorochemical to an 25 
extremely small size-beyond phase microscopy, prob- 
ably to 0.2 pm or less in diameter and possibly to a true 
colloidal dispersion or microemulsion-and are dis- 
persed sufficiently to remain stable in a "solubilized" 
form. In order to be useful in 0 2  and C02 transport, the 30 he: 
emulsions should contain stable dispersions of the fluo- 
15-20% by volume. The pH, electrolyte concentration, 
1. A fluorochemical compound containing 9 to 15 
carbon atoms selected from compounds of the formu- 
rochemical hybrids in a concentration of at least Tf y'f yf 
R/--C-Z or R'j-C-Z-C-R) 
I 1  
R') R'j- 
osmotic and oncotic pressures are adjusted to within 
physiologic range. 35 R'f 
I 
Heat, surface coating, absorption, and the presence of 
air containing 0 2  and N2 all seem to alter the natural and 
biologic action of emulsions of fluorochemicals. It 
seems that carbon dioxide, itself extremely soluble in 
fluorochemicals, is protective to the fluorochemical, 40 
and if all steps in the preparation of the product for 
biologic use are carried out in a CQz atmosphere, the 
finished product is more acceptable biologically, is 
more stable, formation of fluoride ion is inhibited and 
the sonication into small particle sizes is facilitated. By 45 
appropriate filtration such as through a 0.2 micron 
membrane filter, of the emulsified product, particle sizes 
large enough to be biologically harmful can be re- 
moved, the solution can be sterilized (at least bacterio- 
logically), and foreign materials removed. 
The surfactant is present in the emulsion in an amount 
of 1 to 10% by weight usually, about 3 to 6% by weight. 
Suitable surfactants are egg yolk phospholipid, oxygela- 
mers such as Pluronic F.68. Electrolyte can be provided 55 
by a pharmaceutically acceptable saline such as Ring- 
er's solution. 
For perfusion and blood substitute uses the emulsion 
preparation contains sufficient isooncotic agent, typi- 
cally 3% by weight to 10% by weight to make the 60 two of n, n' and nrr are 1. 
emulsion isooncotic and a mixture of salts and bicarbon- 
ate to give the proper ionic strength and pH. 
It is to be realized that only preferred embodiments of 
the invention have been described and that numerous 
ble without departing from the spirit and scope of the 
invention as defined in the following claims. 
where 
RpCnF2,,+ 1 
R i  = C,IF~~, + 1 
Rf'=Cn~~F2,p+ 1 
and n, n' and n" are integers from 1 to 11 and Z is a 
hydrocarbon moiety containing at least 2 hydrogen 
atoms and has a methylene group connected to the 
tertiary carbon atom. 
2. A compound according to claim 1 in which the 
compound contains from 9 to 13 carbon atoms and Z is 
a metabolically reactive hydrocarbon and the com- 
pound has a vapor pressure < 50 mm Hg at 37" C. to 39" 
C. and an oxygen solubility of at least 30 volume per- 
3. A compound according to claim 2 in which Z is 
50 cent at 37.5" C. 
selected from compounds of the formula: 
tin or nonionic ethylene oxide-propylene oxide poly- -CHZ---(CHZ)~-H 
where m is an integer from 0 to 8. 
contains straight chain alkyl groups. 
4. A compound according to claim 3 in which Z 
5. A compound according to claim 1 in which at least 
6. The compound according to Claim 1: 
CF3 
I 
CF3 
CF3 
I 
CF3 
CF3-C-CHz-CHz-CHz-C-CF3 
substitutions, modifications and alterations are permissi- 65 I I 
What is claimed is: 7. The compound according to claim 1: 
9 
CF3 CF3 
4,173,654 
7; 
R~-c=cFc,,F~+ I 
10 
5 I I CF~-C-CH~-CHZ-CH~-CHZ-~-C-CF~ 
I 
CF3 
I 
CF3 
where n is an integer from 0 to 10 with a fluoride ion to 
form a tertiary fluorocarbanion; and 
alkylating the carbanion with an electrophilic rea- 
10 10. An artificial blood substitute comprising a 
gent. 
8. The compound according to claim 1 
fluorohvdrocsrbon aaueous emulsion containinp;: 
an effective amouni of at least 15% by vol&e of a 
fluorochemical compound as defined in claim 5 
1 to 10% by weight of surfactant; and 
remainder physiologically acceptable aqueous car- 
rier. 
11. An emulsion according to claim 10 further includ- 
ing effective amounts of osmotic, pH and oncotic 
agents. 
C F ~ - C F ~ - C F Z - C ( C F ~ ) ~ - H Z ~ H ~ H ~  
15 
9. A method of forming compounds of claim 1 com- 
prising the steps of reacting a fluoroolefin of the for- 
mula: 20 + . + + +  
25 
'30 
35 
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